Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 6/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.54 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20545632 | 1.00 | CYP1A2 (0.55) | CYP1A2CHRM2SLC6A4OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL27837634 | 0.86 | KDM4E (0.63) | CYP1A2CHRM2SLC6A4OPRD1OPRK1 | |
| SCHEMBL19869945 | 0.83 | GAA (0.63) | HTR2AMAPK1KDM4ETDP1HTR2C | |
| SCHEMBL17931046 | 0.82 | CXCR4 (0.55) | CYP1A2CHRM2SLC6A4OPRD1OPRK1 | |
| SCHEMBL22471551 | 0.82 | ALDH1A1 (0.60) | CYP1A2CHRM2SLC6A4OPRD1OPRK1 | |
| SCHEMBL19869933 | 0.78 | CYP1A2 (0.50) | CYP1A2CHRM2SLC6A4OPRD1OPRK1 | |
| SCHEMBL1714907 | 0.76 | SLC6A4 (0.62) | CYP1A2CHRM2SLC6A4OPRD1OPRK1 | |
| SCHEMBL22542166 | 0.76 | CYP1A2 (0.62) | CYP1A2CHRM2SLC6A4OPRD1OPRK1 | |
| SCHEMBL19869944 | 0.76 | KDM4E (0.55) | HTR2AMAPK1KDM4EHTR2CTAAR1 | |
| SCHEMBL7300721 | 0.76 | CYP1A2 (0.62) | CYP1A2CHRM2SLC6A4OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106796-A1 | SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS | FOLLEA INTERNATIONAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INT (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250367232-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | HUTCHINSON FRED CANCER RES (US) | 2025-12-04 | — | — | US | disclosed |
| CN-118756156-A | Method for preparing deuterated cyclic compound | 无锡绿能电合科技有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-12016880-B2 | Halogen treatment of heart attack and ischemic injury | FRED HUTCHINSON CANCER CENTER (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024107708-A1 | TAAR RECEPTOR AGONISTS FOR SEXUAL DYSFUNCTION | ReJoy (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3104939-B1 | TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY WITH SODIUM IODIDE | FRED HUTCHINSON CANCER CENTER (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20220313730-A1 | HALOGEN TREATMENT OF HEART ATTACK AND ISCHEMIC INJURY | FRED HUTCHINSON CANCER CENTER | 2022-10-06 | — | — | US | disclosed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-11337937-B2 | TARR receptor agonists for sexual dysfunction | JOHN MCCOY | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | DYRK4, DYRK2, STRA6 | CYP1A2 3368/4885CHRM2 2954/4885SLC6A4 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.